Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Korean Gliptins Loom Amid Signs Of Shifts In India

Executive Summary

A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon amid what some industry watchers say are early signs of a shake-up in volumes in the highly competitive domestic gliptins market.

Advertisement

Related Content

Permanent Bar Against Glenmark's Sitagliptin Copies
India's mega-gliptins battle: shifting sands?
Glenmark 'pioneers' Mitsubishi's teneligliptin in India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register